Repost: Pharma’s influence over published clinical evidence

Below is a copy of an article I wrote for The Conversation. It’s an independent source of information and analysis about things that matter - but from the university and research perspective, which means it’s generally more rigorous than much of the rest. This article was originally published at The Conversation. Read the original article.   TRANSPARENCY … Continue reading Repost: Pharma’s influence over published clinical evidence

Vested interests in healthcare, as usual

Amy Wang and colleagues from Mayo Clinic write about the tendancy for authors with financial ties to GlaxoSmithKline to write favourably about the drug Rosiglitazone, which has been linked to increased risk of myocardial function and is arguably less useful than another drug on the market, Pioglitazone. Both drugs are used in diabetes care. Fiona … Continue reading Vested interests in healthcare, as usual